1. Induction of erythroferrone in healthy humans by micro-dose recombinant erythropoietin or high-altitude exposure
- Author
-
Annalisa Castagna, Pierre Sallet, Matthieu Roustit, Anne-Kristine Meinild Lundby, Carsten Lundby, Mario Uhr, Elena Gammella, Samuel Verges, Pierre Bouzat, Guillaume Sechaud, Catherine Cornu, Paul Robach, Pierluigi Banco, Stefania Recalcati, Gaetano Cairo, Domenico Girelli, Ecole Nationale des Sports de Montagne (ENSM), Università degli Studi di Milano = University of Milan (UNIMI), Università degli studi di Verona = University of Verona (UNIVR), Centre Hospitalier Universitaire [Grenoble] (CHU), Copenhagen University Hospital, Hypoxie et PhysioPathologie (HP2), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Grenoble Alpes (UGA), Synlab [Lausanne], Centre d'Investigation Clinique [Bron] (CIC1407), Hospices Civils de Lyon (HCL)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Groupement Hospitalier Est [Bron], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), Hôpital Louis Pradel [CHU - HCL], Hospices Civils de Lyon (HCL), Association Athletes For Transparency [Lyon] (2AT), and SALAS, Danielle
- Subjects
medicine.medical_specialty ,Iron ,medicine.medical_treatment ,[SDV]Life Sciences [q-bio] ,SMAD ,doping ,Placebo ,Article ,Mice ,03 medical and health sciences ,0302 clinical medicine ,Hepcidins ,Hepcidin ,hemic and lymphatic diseases ,Internal medicine ,erythroferrone ,medicine ,Animals ,Humans ,Erythropoiesis ,Saline ,030304 developmental biology ,0303 health sciences ,medicine.diagnostic_test ,biology ,business.industry ,Altitude ,fungi ,food and beverages ,Hematology ,Erythroferrone ,[SDV] Life Sciences [q-bio] ,Endocrinology ,Erythropoietin ,Serum iron ,biology.protein ,erythropoietin ,hepcidin ,business ,Iron Metabolism ,030215 immunology ,medicine.drug - Abstract
The erythropoietin (Epo)-erythroferrone (ERFE)-hepcidin axis coordinates erythropoiesis and iron homeostasis. While mouse studies have established that Epo-induced ERFE production represses hepcidin synthesis by inhibiting hepatic BMP/SMAD signaling, evidence for the role of ERFE in humans is limited. To investigate the role of ERFE as a physiological erythroid regulator in humans, we conducted two studies. First, 24 males were given six injections of saline (placebo), recombinant Epo (rhEpo) at a dose of 20 IU/kg (micro-dose) or rhEpo at 50 IU/kg (low dose). Second, we quantified ERFE in 22 subjects exposed to high altitude (3800 m) for 15 h. In the first study, total hemoglobin mass (Hbmass) increased after low- but not after micro-dose injections, when compared to the mass after placebo injections. Serum ERFE levels were enhanced by rhEpo, remaining higher than after placebo for 48 h (micro-dose) or 72 h (low-dose) after injections. Conversely, hepcidin levels decreased when Epo and ERFE rose, before any changes in serum iron parameters occurred. In the second study, serum Epo and ERFE increased at high altitude. The present results demonstrate that in healthy humans ERFE responds to slightly increased Epo levels not associated with Hbmass expansion and downregulates hepcidin in an apparently iron-independent way. Notably, ERFE flags micro-dose Epo, thus holding promise as a novel biomarker of doping.
- Published
- 2020